Navigation Links
Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients
Date:4/1/2011

gated hyperbilirubinemia.  Average alanine aminotransferase (ALT) improved in all BI 201335 groups compared to placebo, and there was no excess anemia reported in the study.  Across BI 201335 treatment groups, 4 to 12 percent of patients discontinued BI 201335 due to AEs.  

(Oral abstract #66) SILEN-C2: Sustained Virologic Response and Safety of BI 201335 Combined with Peginterferon Alfa-2a and Ribavirin in Chronic HCV Genotype-1 Patients with Non-Response to PegIFN/RBVThe SILEN-C2 study evaluated the virological response and safety of different doses of BI 201335 in treatment-experienced patients who did not respond to at least 12 weeks of prior treatment with PegIFN/RBV. This patient population is particularly difficult to treat, as patients who have not responded to PegIFN/RBV alone have low response rates to additional treatments. The trial did not include patients who relapsed after initial treatment with PegIFN/RBV.

In this double-blind, randomized, placebo-controlled trial, 288 treatment-experienced GT-1 HCV patients were randomized (2:1:1) to receive either:

  • BI 201335 240mg QD with a three-day LI of PegIFN/RBV;
  • BI 201335 240mg QD plus PegIFN/RBV without LI; or
  • BI 201335 240mg twice-daily (BID) with a three-day LI of PegIFN/RBV

  • In each group, patients were given BI 201335 for 24 weeks in combination with PegIFN/RBV, which was given for 24 or 48 weeks.

    Patients in the two BI 201335 QD groups who achieved eRVR were re-randomized to either stop all treatment at Week 24 or continue PegIFN/RBV until Week 48.

    Treatment Outcomes in SILEN-C2 (Treatment-Experienced Patients)240mg
    QD/LI
    (N=142)240mg
    QD
    (N=76)240mg
    BID/LI
    (N=70)eRVR, %

    43

    45

    47Overall SVR, %

    28

    41

    31Breakthrough*, %

    25

    28

    17Relapse**, %

    25

    9

    19*Rebound on treatment with BI 20133
    '/>"/>

    SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
    3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
    5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
    7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
    8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
    9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
    10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
    11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/24/2014)... PLAINFIELD, N.J. , July 24, 2014  PTC ... that the Company will host a webcast conference call ... provide an update on the company,s business and outlook ... before the opening of the market. ... (domestic) or (973) 935-8152 (international) five minutes prior to ...
    (Date:7/24/2014)...  Restore Health, a leading personalized medicine company ... it is now offering pharmacogenetics testing that provides ... upon their particular genetic makeup. Comprehensive medication management ... a patient,s genetics and their entire drug regimen.  ... this new service to healthcare providers and their ...
    (Date:7/24/2014)... , Deutschland, und MARSEILLE ... -- , Weltweite ... ermöglicht QIAGEN die Entwicklung von Tests ... für Blutkrebs  Neuer Test weist ... mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf ...
    Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
    ... PharmAthene, Inc. (NYSE Amex: ... biological and chemical threats, announced today that the Company,s ... the position of President and Chief Executive Officer, effective ... Chief Executive Officer in May 2010, and prior thereto ...
    ... Inc., today reported positive clinical trial results on ... inhalation), an antibiotic that is entering Phase III ...  The results demonstrate significant clinical benefit and complete ... of lung infections due to the bacterium, ...
    Cached Medicine Technology:PharmAthene Appoints Eric I. Richman President and Chief Executive Officer 2PharmAthene Appoints Eric I. Richman President and Chief Executive Officer 3ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients 2ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients 3ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients 4ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients 5
    (Date:7/24/2014)... The report, “Content Delivery Networks (CDN) Market”, defines ... with an in-depth analysis and forecasting of revenues. ... this market with insights on trends, opportunities, and ... 36 figures spread through 157 pages and in-depth ... http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . , Early buyers will ...
    (Date:7/24/2014)... Four Seasons Resort Maui at Wailea ... million renovation of the famed Maile suite and the ... in time to welcome summer guests vacationing to this ... the internationally-acclaimed BraytonHughes Design Studios, San Francisco and London, ... the largest in Hawaii—received a complete re-envisioning. No stranger ...
    (Date:7/24/2014)... 2014 The federal judge overseeing ... in the U.S. District Court, District of Massachusetts, ... medical information covered by the federal Health Insurance ... 16th Order, U.S. District Judge Douglas P. Woodlock ... Care the right to receive HIPAA- protected information. ...
    (Date:7/24/2014)... (PRWEB) July 24, 2014 Just as ... they must consider their own financial and marketing strength ... weak marketing campaigns to the next level by using ... Call Center, IVR, Voice Broadcast, Call Tracking and ... 98% open rate, text messages are quickly become integral ...
    (Date:7/24/2014)... 24, 2014 In a July 9th article ... founder of Lotus Blossom Consulting LLC , was quoted ... Three Ways to Cut the High Cost of Infertility . ... costs is to maximize your chance of success from the ... a clinic. , “I am always happy to talk ...
    Breaking Medicine News(10 mins):Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 4Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 5Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 4Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 2Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 3Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 2Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 3
    ... 3 The National,Fibromyalgia Association today announced that ... III, will be its designated spokeswoman to,help raise ... illness that experts believe affects up to 10 ... Mrs. Bremer was diagnosed with fibromyalgia 25 ...
    ... join Terrence Howard, Natalie, Maines and Abigail Breslin to ... ... SAN FRANCISCO, Oct. 3 Gap is proud to,introduce ... to help eliminate AIDS in Africa. Captured by acclaimed,photographer Annie ...
    ... /PRNewswire-FirstCall/ - Predictive medicine company,PreMD Inc. (TSX: PMD; ... on the,company,s 510(k) application to the US Food ... On Wednesday, October 3, 2007, Dr. Brent ... present at BioContact Quebec, a leading,annual biopharmaceutical conference. ...
    ... New research from the Howard Florey Institute in Melbourne ... cause epilepsy in infants. , Infants are more susceptible ... rapid rate, making their brain cells excitable. Their neurons ... cells, which can disrupt normal brain activity and results ...
    ... Laboratory (EMBL), the University of Helsinki, Finland, the ... officially launch their new Nordic EMBL Partnership for ... and collaborations between the partners and will facilitate ... for an initial period of five years. ...
    ... spur these outbursts , WEDNESDAY, Oct. 3 (HealthDay News) ... problems can help prompt dogs to bite children, a ... Pennsylvania looked at 111 cases involving 103 dogs that ... clinic over four years. , "Guarding of resources and ...
    Cached Medicine News:Health News:Frances Winfield Bremer, Wife of Ambassador L. Paul Bremer, III, to Become Spokeswoman for the National Fibromyalgia Association 2Health News:Gap Introduces Inspirational Marketing Campaign to Celebrate First Anniversary of Global Launch of Gap (PRODUCT) RED 2Health News:Gap Introduces Inspirational Marketing Campaign to Celebrate First Anniversary of Global Launch of Gap (PRODUCT) RED 3Health News:Gap Introduces Inspirational Marketing Campaign to Celebrate First Anniversary of Global Launch of Gap (PRODUCT) RED 4Health News:PreMD Inc. Provides Corporate Update 2Health News:PreMD Inc. Provides Corporate Update 3Health News:Research shows how genetic mutation causes epilepsy in infants 2Health News:EMBL reaches north 2Health News:Medical, Behavioral Woes Can Drive Dogs to Bite 2
    ... for strength and durability. Four 64 mirrors ... minimal lens rotation. Choice of three handles ... Small diameter contact surface allows static or ... polymer coating protects mirrors and is compatible ...
    ... Three mirrors of 64, 67 ... diameter contact surface for use ... be viewed through the central ... polymer coating protects mirrors and ...
    Small size gonio lens with one 62 mirror. Compact knurled ring simplifies 360 viewing of the anterior chamber angle....
    Lacrimal cannula blunt tip with 0.3 mm side port, straight....
    Medicine Products: